Found: 70
Select item for more details and to access through your institution.
Outcomes of patients with limited‐stage plasmablastic lymphoma: A multi‐institutional retrospective study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 2, p. 300, doi. 10.1002/ajh.26784
- By:
- Publication type:
- Article
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003–2018).
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1150, doi. 10.1002/ajh.26635
- By:
- Publication type:
- Article
Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 979, doi. 10.1002/ajh.26230
- By:
- Publication type:
- Article
Testicular FDG‐PET/CT uptake threshold in aggressive lymphomas.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 3, p. E81, doi. 10.1002/ajh.26073
- By:
- Publication type:
- Article
Holistic review for hematology‐oncology fellowship applicants: A new paradigm?
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 10, p. 1124, doi. 10.1002/ajh.25930
- By:
- Publication type:
- Article
Detection of extranodal and spleen involvement by FDG‐PET imaging predicts adverse survival in untreated follicular lymphoma.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 7, p. 786, doi. 10.1002/ajh.25493
- By:
- Publication type:
- Article
Role of systemic high‐dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990‐2018.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 3, p. 291, doi. 10.1002/ajh.25350
- By:
- Publication type:
- Article
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. 1156, doi. 10.1002/ajh.24864
- By:
- Publication type:
- Article
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 5, p. 448, doi. 10.1002/ajh.24671
- By:
- Publication type:
- Article
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 5, p. 467, doi. 10.1002/ajh.24693
- By:
- Publication type:
- Article
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 11, p. 1096, doi. 10.1002/ajh.24492
- By:
- Publication type:
- Article
Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non- Hodgkin lymphoma.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 12, p. 1116, doi. 10.1002/ajh.23839
- By:
- Publication type:
- Article
The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 9, p. 865, doi. 10.1002/ajh.23760
- By:
- Publication type:
- Article
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and <sup>90</sup>yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 7, p. 589, doi. 10.1002/ajh.23460
- By:
- Publication type:
- Article
RNAseq identification of FISH‐cryptic BCL6::TP63 rearrangement in ALK‐negative anaplastic large‐cell lymphoma.
- Published in:
- Histopathology, 2022, v. 81, n. 2, p. 275, doi. 10.1111/his.14674
- By:
- Publication type:
- Article
Treatment of Aggressive B Cell Lymphomas: Updates in 2019.
- Published in:
- Current Hematologic Malignancy Reports, 2020, v. 15, n. 3, p. 225, doi. 10.1007/s11899-020-00581-6
- By:
- Publication type:
- Article
Molecular Subtypes of DLBCL and Choice of Therapy -- 20 years in Making.
- Published in:
- Oncology (08909091), 2019, v. 33, n. 10, p. 405
- By:
- Publication type:
- Article
T cell/histiocyte‐rich large B cell lymphoma: incidence, demographic disparities, and long‐term outcomes.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 140, doi. 10.1111/bjh.15391
- By:
- Publication type:
- Article
Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Oncologist, 2023, v. 28, n. 3, p. 199, doi. 10.1093/oncolo/oyac256
- By:
- Publication type:
- Article
Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00942-3
- By:
- Publication type:
- Article
Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 8, p. e815, doi. 10.1016/j.clml.2022.04.009
- By:
- Publication type:
- Article
MCL-042: Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S408, doi. 10.1016/S2152-2650(21)01919-4
- By:
- Publication type:
- Article
ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S392, doi. 10.1016/S2152-2650(21)01891-7
- By:
- Publication type:
- Article
ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S376, doi. 10.1016/S2152-2650(21)01860-7
- By:
- Publication type:
- Article
Poster: MCL-042: Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S246, doi. 10.1016/S2152-2650(21)01551-2
- By:
- Publication type:
- Article
Poster: ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01533-0
- By:
- Publication type:
- Article
Poster: ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S239, doi. 10.1016/S2152-2650(21)01499-3
- By:
- Publication type:
- Article
A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00847-1
- By:
- Publication type:
- Article
Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00847-1
- By:
- Publication type:
- Article
PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 5, p. 1, doi. 10.1038/s41408-022-00649-x
- By:
- Publication type:
- Article
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41408-021-00598-x
- By:
- Publication type:
- Article
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 9, p. 1, doi. 10.1038/s41408-021-00542-z
- By:
- Publication type:
- Article
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 7, p. 1, doi. 10.1038/s41408-021-00525-0
- By:
- Publication type:
- Article
Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00394-z
- By:
- Publication type:
- Article
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 11, p. 1, doi. 10.1038/s41408-020-00382-3
- By:
- Publication type:
- Article
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 9, p. N.PAG, doi. 10.1038/s41408-019-0233-5
- By:
- Publication type:
- Article
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 6, p. N.PAG, doi. 10.1038/s41408-019-0208-6
- By:
- Publication type:
- Article
Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma.
- Published in:
- Frontiers in Genetics, 2022, v. 13, p. 1, doi. 10.3389/fgene.2022.826594
- By:
- Publication type:
- Article
Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma.
- Published in:
- Frontiers in Genetics, 2022, v. 13, p. 1, doi. 10.3389/fgene.2022.826594
- By:
- Publication type:
- Article
The Richardson/Schlossman/Hideshima et at Article Reviewed.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 14, p. 1796
- By:
- Publication type:
- Article
Safety and efficacy of durvalumab with R-CHOP or R<sup>2</sup>-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.
- Published in:
- International Journal of Hematology, 2022, v. 115, n. 2, p. 222, doi. 10.1007/s12185-021-03241-4
- By:
- Publication type:
- Article
Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis.
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 5, p. 1221, doi. 10.1093/cid/ciz940
- By:
- Publication type:
- Article
Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 2, p. 210, doi. 10.1111/bjh.17691
- By:
- Publication type:
- Article
Impact of metformin use on the outcomes of newly diagnosed diffuse large B‐cell lymphoma and follicular lymphoma.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 6, p. 820, doi. 10.1111/bjh.15997
- By:
- Publication type:
- Article
T cell/histiocyte‐rich large B cell lymphoma: incidence, demographic disparities, and long‐term outcomes.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 1, p. 140, doi. 10.1111/bjh.15391
- By:
- Publication type:
- Article
Event‐free survival at 24 months captures central nervous system relapse of systemic diffuse large B‐cell lymphoma in the immunochemotherapy era.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 1, p. 149, doi. 10.1111/bjh.14922
- By:
- Publication type:
- Article
Human Pegivirus infection and lymphoma risk and prognosis: a North American study.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 5, p. 644, doi. 10.1111/bjh.15416
- By:
- Publication type:
- Article
Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 1, p. 50, doi. 10.1111/bjh.14813
- By:
- Publication type:
- Article
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 3, p. 427, doi. 10.1111/bjh.14688
- By:
- Publication type:
- Article